Stockscreener 앱 받기
0.5453
0.98%
0.0053
Century Therapeutics Inc 주식(IPSC)의 최신 뉴스
What analysts say about Century Therapeutics Inc stockStraddle and Strangle Trades & Double Or Triple Wealth - earlytimes.in
Century Therapeutics 'moving with urgency' to develop drug for Type 1 diabetes - The Business Journals
Century Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference - Investing News Network
There is no way Century Therapeutics Inc (IPSC) can keep these numbers up - Setenews
[Form 4] Century Therapeutics, Inc. Insider Trading Activity - Stock Titan
Century Therapeutics Debuts Immune-Evasive Cell Therapy Aiming to Transform Type 1 Diabetes - MSN
Century Therapeutics Unveils iPSC Beta Islet Program as Cash Runway Extends Into 2027 - MSN
Century Therapeutics Executive Acquires 35,000 Shares - TradingView
Chmn Pfeiffenberger Buys 35,000 ($17.3K) Of Century Therapeutics Inc [IPSC] - TradingView
Officer Cowan Files To Sell 5,462 Of Century Therapeutics Inc [IPSC] - TradingView
Research Analysts Set Expectations for IPSC FY2025 Earnings - Defense World
Century Therapeutics Inc. stock momentum explainedMarket Performance Recap & Weekly Stock Performance Updates - newser.com
What machine learning models say about Century Therapeutics Inc.2025 Fundamental Recap & Daily Technical Forecast Reports - newser.com
Century Therapeutics Executive Sells Shares to Cover Tax Obligations - TradingView
Real time pattern detection on Century Therapeutics Inc. stockIPO Watch & Safe Capital Growth Trade Ideas - newser.com
Leerink Partners Reaffirms “Market Perform” Rating for Century Therapeutics (NASDAQ:IPSC) - Defense World
Leerink Partnrs Downgrades Century Therapeutics (NASDAQ:IPSC) to Hold - Defense World
Take off with Century Therapeutics Inc (IPSC): Get ready for trading - Setenews
What technical signals suggest for Century Therapeutics Inc. stockCPI Data & Accurate Entry and Exit Point Alerts - newser.com
How Century Therapeutics Inc. stock compares to industry benchmarksMarket Trend Summary & Free Expert Approved Momentum Trade Ideas - newser.com
Century Therapeutics Shares Fall After Leerink Partners Downgrade - MarketScreener
IPSC Stock Downgraded by Leerink Partners: Price Target Slashed - GuruFocus
Leerink Partners Downgrades Century Therapeutics to Market Perform From Outperform, Price Target is $7 - MarketScreener
Century Therapeutics stock downgraded by Leerink Partners on lack of catalysts - Investing.com Canada
Leerink Partners Downgrades Century Therapeutics to Market Perform From Outperform - MarketScreener
What Fibonacci levels say about Century Therapeutics Inc. reboundRisk Management & Free Technical Confirmation Trade Alerts - newser.com
Analyzing drawdowns of Century Therapeutics Inc. with statistical toolsQuarterly Market Summary & AI Powered Market Entry Strategies - newser.com
Century Therapeutics Inc. stock trend outlook and recovery pathWeekly Trade Recap & High Accuracy Investment Entry Signals - newser.com
Published on: 2025-11-15 03:30:02 - newser.com
Can volume confirm reversal in Century Therapeutics Inc.2025 Trading Volume Trends & Weekly High Conviction Trade Ideas - newser.com
Century Therapeutics unveils β islet program for type 1 diabetes - BioWorld MedTech
Century Therapeutics Reports Positive Q3 2025 Earnings - TipRanks
Century Therapeutics Shrinks Costs But Net Loss Widens - Finimize
Century Therapeutics Inc. stock trendline breakdownPortfolio Growth Summary & Daily Technical Stock Forecast Reports - newser.com
Century Therapeutics unveils T1D therapy program with immune evasion tech By Investing.com - Investing.com Nigeria
Century Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - Investing News Network
[8-K] Century Therapeutics, Inc. Reports Material Event | IPSC SEC FilingForm 8-K - Stock Titan
Century Therapeutics Announces New Beta Islet Program for Type 1 Diabetes - Investing News Network
Century Therapeutics Q3 net loss widens, despite lower costs - MarketScreener
Century Therapeutics, Inc. SEC 10-Q Report - TradingView
Century Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
[10-Q] Century Therapeutics, Inc. Quarterly Earnings Report | IPSC SEC FilingForm 10-Q - Stock Titan
Century Therapeutics unveils T1D therapy program with immune evasion tech - Investing.com
Century Therapeutics Announces Breakthrough Allo-Evasion™ 5.0 iPSC Beta Islet Therapy for Type 1 Diabetes with Plans for IND Submission by 2026 - Quiver Quantitative
0.45%
1.13%
자본화:
|
볼륨(24시간):